Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

WallStreetBuyDip Nov. 16 at 11:04 PM

$EDIT sitting at $3 with volume 38% below average, while $BNTX trading at $103 with 40% above average volume. BNTX showing strength in the Genomics sector with a significant price difference. Will the sector momentum continue to favor higher-priced stocks like BNTX?

0 · Reply

StockBraker Nov. 16 at 12:55 PM

$EDIT https://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-given-average-recommendation-of-hold-by-brokerages-2025-11-14/

0 · Reply

Whoami1989 Nov. 14 at 9:03 PM

$EDIT this stock has lost 99.9% of market value in 3 years, and it has no product.

0 · Reply

Whoami1989 Nov. 14 at 8:40 PM

$EDIT hey idiotic cheerleaders!!! did you load it up? if you do, you are f stupid

0 · Reply

Whoami1989 Nov. 14 at 8:27 PM

$EDIT simply put mf fpos

0 · Reply

Whoami1989 Nov. 14 at 8:19 PM

$EDIT time for idiotic day traders to cash out for beers and prostitution on weekend

1 · Reply

Whoami1989 Nov. 14 at 7:27 PM

$EDIT this fpos is dead

0 · Reply

Ebrice73 Nov. 14 at 7:03 PM

$EDIT

0 · Reply

Whoami1989 Nov. 14 at 4:48 PM

$EDIT fpos can’t get erection day

0 · Reply

0x126 Nov. 14 at 2:13 PM

$EDIT how the value of 3 months is erased because a competitor had one sick patient of 600 die. The overreaction in US bio is insane.

0 · Reply

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 13 days ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 14, 2025, 6:18 PM EDT - 4 weeks ago

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 5 weeks ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 5 weeks ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 2 months ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 2 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 27, 2025, 9:00 AM EDT - 2 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 12, 2025, 4:01 PM EDT - 3 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 5 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 6 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 6 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 6 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 6 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 6 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 6 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 6 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 6 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 7 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 8 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 8 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 8 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 9 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 9 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 9 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 10 months ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 10 months ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 10 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 11 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Aug 7, 2024, 12:03 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

WallStreetBuyDip Nov. 16 at 11:04 PM

0 · Reply

StockBraker Nov. 16 at 12:55 PM

$EDIT https://www.marketbeat.com/instant-alerts/editas-medicine-inc-nasdaqedit-given-average-recommendation-of-hold-by-brokerages-2025-11-14/

0 · Reply

Whoami1989 Nov. 14 at 9:03 PM

$EDIT this stock has lost 99.9% of market value in 3 years, and it has no product.

0 · Reply

Whoami1989 Nov. 14 at 8:40 PM

$EDIT hey idiotic cheerleaders!!! did you load it up? if you do, you are f stupid

0 · Reply

Whoami1989 Nov. 14 at 8:27 PM

$EDIT simply put mf fpos

0 · Reply

Whoami1989 Nov. 14 at 8:19 PM

$EDIT time for idiotic day traders to cash out for beers and prostitution on weekend

1 · Reply

Whoami1989 Nov. 14 at 7:27 PM

$EDIT this fpos is dead

0 · Reply

Ebrice73 Nov. 14 at 7:03 PM

$EDIT

0 · Reply

Whoami1989 Nov. 14 at 4:48 PM

$EDIT fpos can’t get erection day

0 · Reply

0x126 Nov. 14 at 2:13 PM

$EDIT how the value of 3 months is erased because a competitor had one sick patient of 600 die. The overreaction in US bio is insane.

0 · Reply

Whoami1989 Nov. 13 at 8:37 PM

$EDIT when market is down, fpos is fked. When market is up, fpos is shitty. therefore it is so fking potential

0 · Reply

Robert_Dempster Nov. 13 at 7:08 PM

$EDIT market is selling off today turning into a buying opportunity here🐂

1 · Reply

Whoami1989 Nov. 13 at 6:42 PM

$EDIT the best loser of all.

0 · Reply

Whoami1989 Nov. 13 at 3:48 PM

$EDIT simply put fpos

0 · Reply

harryvanluik Nov. 13 at 3:04 PM

$EDIT this should be exploding i.s.o. imploding

1 · Reply

NancyPelosiStonks Nov. 12 at 6:43 PM

$EDIT 🚀🚀🚀🚀💸💸💸💰💰💰 loaded up and ready for the run

0 · Reply

Robert_Dempster Nov. 12 at 9:49 AM

$EDIT going to be moving up here higher highs and higher lows📈🐂💰

0 · Reply

Ebrice73 Nov. 11 at 11:08 PM

$EDIT Share Price: $2.65 Buy Zone: $2.45- $3.30 Target Zone: $4.85 – $6.30 for January 3rd Potential Upside: 121% ROI 🤙

0 · Reply

SuperGreenToday Nov. 11 at 10:25 PM

$EDIT Share Price: $2.65 Contract Selected: Feb 20, 2026 $0.5 Calls Buy Zone: $1.32 – $1.63 Target Zone: $2.11 – $2.57 Potential Upside: 51% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Whoami1989 Nov. 11 at 7:57 PM

$EDIT again the market continues really, and this fpos is barely shitty

1 · Reply

harryvanluik Nov. 11 at 6:26 PM

$EDIT This is a once in a lifetime opportunity: a real turnaround stock with hugh upside potential!

0 · Reply

PMFRTiger Nov. 11 at 4:20 PM

$EDIT bottom? For good..

0 · Reply

Market Cap	253.81M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,769,600
Avg Vol	2,741,934
Day's Range	N/A - N/A
Shares Out	97.62M
Stochastic %K	42%
Beta	2.23
Analysts	Sell
Price Target	$3.65